LAGUNA HILLS, Calif., April 14 /PRNewswire/ -- Symphony Medical, Inc., a developer of novel biopolymer therapies to cardiac abnormalities, announced today that its patented flagship technology, Algisyl-LVR(R), was used on a human for the first time, successfully treating a 50-year-old male who was suffering from chronic heart failure.

The Company intends to sponsor a clinical study of Algisyl-LVR at four centers in Europe, including the German Heart Center in Munich where the first procedure was performed, and is also seeking an Investigational Device Exemption from the U.S. Food and Drug Administration in order to conduct a follow-on U.S. study.

Algisyl-LVR is an implantable medical device under clinical development intended to prevent or reverse the progression of congestive heart failure in patients who have an enlarged left ventricle. The procedure, which is performed on patients undergoing a planned cardiac surgery for mitral valve regurgitation or coronary artery disease, involves injecting a proprietary biopolymer directly into strategic locations of the heart's left ventricle wall. As it is injected, the biopolymer thickens and forms firm, gel-like structures that remain in the heart muscle as permanent implants. These implants act to re-shape the heart, reduce the size of the dilated left ventricle and thicken the damaged wall of the heart, thus returning the heart to a healthier form that facilitates improved cardiac function and performance.

The first Algisyl-LVR patient was successfully treated by Prof. Dr. Robert Bauernschmitt. The condition of the patient, who had been bedridden, was deteriorating due to a poorly performing heart mitral valve which contributed to congestive heart failure. During the surgery to repair the valve, the cardiac surgeon implanted the Algisyl-LVR. Four days following '/>"/>

... to record the electrophysiology of sleep in a wild ... hours per day6 hours less than captive sloths did, ... Smithsonian Tropical Research Institutes Barro Colorado Island in Panama., ... than others. If we can determine the reasons for ...

... Portfolio of Advanced Flow Cytometry Platforms, FRANKLIN LAKES, ... BDX ) announced today that it has acquired ... Washington,corporation based in Seattle that develops and markets advanced ... transaction were not disclosed. The acquisition,is not expected to ...

... Md., May 13 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... services and products in the People,s Republic of China,announced ... the,Securities and Exchange Commission (SEC) that, if declared effective ... time to time, up to $100 million,of its common ...

(Date:7/7/2015)... , July 7, 2015 Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...

(Date:7/2/2015)... , July 2, 2015 Fingerprint ... FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... The sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of approximately 2,200 ...

... Thailand and Morocco have found that DHEA-S may prevent ... patients. In a report appearing in the February 2013 ... they describe how a network of steroid molecules found ... infection leading to brain damage. This suggests that treatment ...

... skin is a human being,s largest sensory organ, helping to ... negative sensation, like a pinch or a burn. Previous studies ... by different types of sensory neurons that have nerve endings ... have been identified, however, and most of those detect painful ...

... The National Science Foundation has notified Oregon State University that ... finalize the design and coordinate the construction of as many ... science research capabilities of the United States. OSU initially ... of the project and if funds are appropriated for ...